For patients with prostate cancer treated with androgen deprivation therapy there are increases in components of metabolic syndrome and in the prevalence of full metabolic syndrome, according to a study published in The Journal of Urology.
Juan Morote, M.D., from Hospital Vall d’Hebron and Universitat Autónoma de Barcelona in Spain, and colleagues conducted an observational prospective study involving 539 prostate cancer patients scheduled to receive three-month depot luteinizing hormone-releasing hormone analogs for longer than 12 months.
The authors examined the prevalence of full metabolic syndrome, assessed according to different definitions, and its components.
The researchers found that at six and 12 months after androgen deprivation therapy initiation there were significant increases in waist circumference, body mass index, fasting glucose, triglycerides, total cholesterol, and high- and low-density lipoprotein cholesterol.
There were no significant changes in blood pressure of 130/85 mm Hg or greater. There was a nonsignificant increase in the prevalence of full metabolic syndrome, based on National Cholesterol Education Program Adult Treatment Panel III criteria (baseline, 22.9 percent versus 25.5 percent at six months and 26.8 percent at 12 months).
RELATED: Prostate Cancer Working Group Updates CRPC Clinical Trial Guidelines
At 12 months there were significant increases in metabolic syndrome prevalence with two of the definitions (World Health Organization, 4.1 percent and American Heart Association/National Heart, Lung, and Blood Institute, 8.1 percent).
“Counseling patients on the prevention, early detection, and treatment of specific metabolic alterations is recommended,” the authors write.
The study was funded by Ipsen Pharma.